{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002291285,0.0002651981,0.001464583,0.00007096156,0.0001871876,0.00006841885,0.0009037923,0.000193025,0.00342083],"category_scores_gemma":[0.0001515914,0.0001594262,0.00008639585,0.0002056858,0.0003740473,0.0001681933,0.0001712554,0.0004658154,0.00005667477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003783031,"about_ca_system_score_gemma":0.001756256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006577065,"about_ca_topic_score_gemma":0.0002330917,"domain_scores_codex":[0.9966963,0.001062556,0.0006635443,0.0004621184,0.0004041742,0.0007112891],"domain_scores_gemma":[0.997268,0.0007588344,0.000323923,0.0007664455,0.0006293235,0.0002534773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7537297,0.006436328,0.00009198448,0.0001540822,0.0003289649,0.00001873378,0.001210447,0.000008798616,0.06695408,0.0002454347,0.02794383,0.1428776],"study_design_scores_gemma":[0.8416265,0.03362902,0.0005422068,0.0002114615,0.0000697222,0.00007815054,0.0002075896,0.00118266,0.01226596,0.0003922259,0.1095839,0.0002105746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.5985378,0.0001055015,0.00005980228,0.0296968,0.0003528013,0.3638335,0.0003623278,0.00006158224,0.00698982],"genre_scores_gemma":[0.2191866,0.0002006208,0.001731819,0.00641992,0.002317748,0.7685046,0.00007909544,0.00009989448,0.001459712],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.404671,"threshold_uncertainty_score":0.9974902,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1888122349117266,"score_gpt":0.5311267806640083,"score_spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}